Xenetic Bio - Multiplikator nilai perusahaan marang pendapatan XBIO

Xenetic Biosciences (XBIO) is collaborating with oncology centers to develop enzyme-based agents to enhance immunotherapy. The innovative XCART platform for personalized blood treatment is strengthening investor confidence, as evidenced by the available EV/Revenue multiple in the GURU.Markets system. The current -743.24 figure reflects the state of the metric while the company relies on B2B licensing while awaiting FDA approval for its cell technologies.
Rincian metrik keuangan lan pasar Xenetic Biosciences, Inc. (XBIO)

This indicator determines the enterprise value minus net debt relative to sales volume, eliminating the impact of debt load on the fundamental valuation. By analyzing the change in enterprise value to revenue, the investor assesses the operational resilience of Xenetic Biosciences (XBIO) prior to the commercialization of DNase-based drugs and the receipt of royalties from the PolyXen platform in the oncotherapy segment.